RH324 for Advanced Lung Cancer

Overseen By Charles Packard

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: ReHeva Biosciences,Inc.

Must not be taking: Cytochrome P450 inhibitors

Disqualifiers: Cardiac risk, HIV, active infection, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

6 Participants Needed

Trial Summary

What is the purpose of this trial?

Phase 1 open label dose ranging study of RH324 in advanced non-small cell lung cancer

Eligibility Criteria

Adults over 18 with advanced non-small cell lung cancer who have tried all standard treatments without success. They must not be pregnant, agree to birth control, and abstain from alcohol and supplements. Participants need a life expectancy of more than 2 months, adequate organ function, no serious medical conditions or infections, and the ability to swallow capsules.

Inclusion Criteria

My thyroid function is normal.

You should not consume alcohol or dietary supplements.

Not pregnant, lactating and willing to use birth control throughout study

Exclusion Criteria

I need medication that strongly affects liver enzyme activity.

I have risk factors for heart disease.

I do not have any unstable health conditions.

Treatment Details

Interventions

• RH324

Trial Overview The trial is testing RH324, an oral medication for advanced non-small cell lung cancer. It's a phase 1 study which means it's early in testing and focuses on finding the right dose. Patients will take this drug to see how well it works and what doses are safe.

Participant Groups

Group I: Dose Level 3 Experimental Treatment 1 Intervention

RH324

Group II: Dose Level 2 Experimental Treatment 1 Intervention

RH324

Group III: Dose Level 1 Experimental Treatment 1 Intervention

RH324

Who Is Running the Clinical Trial?

ReHeva Biosciences,Inc.

Lead Sponsor

Trials

1

Recruited

6+